Truist Securities Maintains Buy on Pfizer, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has maintained a 'Buy' rating on Pfizer (NYSE:PFE) but lowered the price target from $62 to $42.
October 17, 2023 | 5:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer's price target has been lowered from $62 to $42 by Truist Securities, although the 'Buy' rating is maintained.
The lowering of the price target by Truist Securities could potentially lead to a short-term negative impact on Pfizer's stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100